Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selinexor + bortezomib + dexamethasone in progressive or refractory multiple myeloma
NL-OMON44193Phase 2Recruiting
- Sponsor
- Erasmus MC
- Start
- Jan 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of selinexor in multiple myeloma (MM) (2 arms), sponsored by Erasmus MC. Primary endpoints: Dose-limiting toxicity, Recommended dose level and 1 more. Started Jan 2015; status: recruiting.
02
Drugs
selinexor
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NL-OMON44193.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44193.